Pradusinstobart - Lyvgen Biopharma
Alternative Names: Anti-PD1 antibody - Lyvgen Biopharma; LVGN-3616Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Lyvgen Biopharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Solid tumours
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 28 Dec 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Cancer in China (IV, Infusion)